N@N

Protox reports 2009 third quarter results

^{Published on 2009-11-16 04:08:20 - Market Wire}
 

 - Completed patient enrollment in the TRIUMPH Phase 2b study, a multi-centre, double-blinded, placebo controlled trial evaluating PRX302 in 92 males with moderate to severe benign prostatic hyperplasia (BPH). Top line results from the study are anticipated in December 2009 or early January 2010. - Announced positive 12 month data from the open-label Phase 2 study of PRX302, indicating that males with moderate to severe BPH who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment. No safety issues were identified in this study and no sexual dysfunction has been reported in any of the subjects dosed to date. Detailed data from this study were presented at the 30th World Congress of the Société Internationale d'Urologie Conference on November 2nd, 2009.